This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Gilead Buying CV Therapeutics for $1.4B

Updated from 12:59 p.m. EDT

Gilead Sciences (GILD - Get Report) is acquiring CV Therapeutics (CVTX) in a $1.4 billion cash deal that will boost Gilead's nascent cardiovascular drug franchise, the companies announced Thursday.

The acquisition values CV Therapeutics at $20 a share, or a 25% premium to the stock's closing price Wednesday. Gilead is swooping in with a higher offer for CV Therapeutics after Japanese drug maker Astellas sought to buy the company for $16 a share, an offer that was rebuffed multiple times by CV Therapeutics' board of directors.

Gilead is best known for its market-leading HIV drug franchise, but the company has recently branched out with drugs to treat pulmonary and cardiovascular disease. CV Therapeutics owns Ranexa, a drug to treat chronic angina, and Lexiscan, a cardiac stress agent.

Gilead is developing a new drug, darusentan, for persistent hypertension. Data from two phase III studies of darusentan are expected later this year.

"The acquisition of CV Therapeutics represents a unique opportunity to complement and strengthen our growing cardiovascular portfolio," said Gilead chairman and CEO John Martin.

Gilead says the acquisition of CV Therapeutics will be dilutive to earnings in 2009 and neutral to accretive in 2010.

Gilead shares were gaining 0.9% to $43.43 in recent trading.

Te Gilead-CV merger follows a slew of drug-firm deals in recent weeks, including Roche's purchase of Genentech (DNA) -- also announced Thursday -- Merck's (MRK - Get Report) $41 billion merger with Schering-Plough (SGP), and Pfizer's (PFE - Get Report) $68 billion acquisition of Wyeth (WYE)

At the time of publication, Feuerstein's Biotech Select model portfolio was long Gilead Sciences, CV Therapeutics and Genentech.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
GILD $103.53 0.00%
MRK $58.54 0.00%
PFE $34.32 0.00%
AAPL $128.46 0.00%
FB $78.97 0.00%


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs